logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Gilead Sciences: The FDA Approved Yescarta® - The First CAR T-Cell Therapy for Initial Treatment of Relapsed or Refractory LBCL

Gilead Sciences' Product Yescarta Kite - a Gilead Sciences ( GILD ) Company, announced the U.S. FDA has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma ( LBCL ) refractory to first-line chemo-immunotherapy or that which...

Read More

April 4, 2022

0

Promising Agreement Between Jazz Pharmaceuticals and Werewolf Therapeutics

Jazz Pharmaceuticals and Werewolf Therapeutics Agreement Jazz Pharmaceuticals ( JAZZ ) and Werewolf Therapeutics ( HOWL ) entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha...

Read More

April 8, 2022

0

Why Kala Pharmaceuticals Stock is Soaring

Kala Pharmaceuticals  Kala Pharmaceuticals ( KALA )  announced today that the U.S. FDA has accepted the investigational new drug application ( IND ) for its lead product candidate, KPI-012, a human Mesenchymal Stem Cell Secretome ( MSC-S ) for the...

Read More

December 28, 2022

0

Aslan Pharmaceuticals: A Small Firm with Early, Promising Results for Atopic Dermatitis

Aslan Pharmaceuticals  Aslan Pharmaceuticals ( ASLN ) is a clinical-stage immunology company announced positive interim unblinded data from three dose cohorts of its ongoing randomized, double-blind placebo-controlled multiple ascending dose study of ASLAN-004 for moderate to severe atopic dermatitis.  ...

Read More

March 1, 2021

0

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

CytomX and Moderna in the NEWS On January 05, 2023,  CytomX Therapeutics ( CTMX ) and Moderna Inc ( MRNA )  announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna’s mRNA technologies and CytomX’s Probody therapeutic...

Read More

January 5, 2023

0

Gilead Sciences: Remdesivir is the First and Only Approved Treatment for Pediatric Patients with COVID-19. See Also: Cassava Sciences

Gilead Sciences Receives sNDA from the FDA for Remdesivir for Pediatric Patients with COVID-19 Gilead Sciences ( GILD ) announced that the U.S. Food and Drug Administration ( FDA ) has approved a supplemental new drug application ( sNDA )...

Read More

April 26, 2022

0

The Reasons Why Ovid Therapeutics' Stock Outperformed Today

Ovid Therapeutics & Takeda Announce Agreement for Soticlestat Ovid Pharmaceuticals is eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales Potential first-in-class therapy reduced...

Read More

March 3, 2021

0

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise

Shoreline Biosciences to Acquire Editas Medicine’s iNK cell franchise Editas Medicine, Inc. ( EDIT ) , announced that it has entered into a definitive agreement with the private Shoreline Biosciences (Shoreline) to license Editas Medicine’s proprietary SLEEK (SeLection by Essential-gene Exon...

Read More

January 19, 2023

0

Amgen: Repatha Studies Showed Sustained Reduction in Low-Density Lipoprotein Cholesterol with No New Safety Findings

Amgen Repatha Studies Repatha is the Longest Studied PCSK9i Amgen ( AMGN ) announced top-line results from two Repatha® (evolocumab) open label extension ( OLE ) studies to the Phase 3 FOURIER cardiovascular outcomes trial. The studies were designed to assess...

Read More

April 27, 2022

0

Vertex Provided Successful Results of VX-880 for Type 1 Diabetes Then Placed the Product on Clinical Hold

A lot is happening while the Stock Market is tanking and is finally being considered a Bear Market. Trading in this Market as it is now is more like gambling rather than trading. We are working hard towards evaluating our...

Read More

May 2, 2022

0

  • Previous
  • 1
  • 2
  • ...
  • 132
  • 133
  • 134
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy